Temasek leads $65m Series D round in US-based SQZ Biotechnologies

Photo by Louis Reed on Unsplash

Singapore state investor Temasek has led a $65-million Series D round in SQZ Biotechnologies Company (SQZ), a US-based clinical-stage cell therapy company, according to an announcement.

The round saw participation from GV, Illumina Ventures, Invus, JDRF T1D Fund, NanoDimension, and Polaris Partners.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter